Technical Analysis for AYTU - Aytu BioScience, Inc.

Grade Last Price % Change Price Change
F 1.94 0.91% 0.02
AYTU closed up 0.91 percent on Friday, November 1, 2024, on 43 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 12
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Gapped Up Strength 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 0.91%
Lower Bollinger Band Walk Weakness 0.91%
New 52 Week Low Weakness 0.91%
Below Lower BB Weakness 0.91%
Down 3 Days in a Row Weakness 0.91%
Down 4 Days in a Row Weakness 0.91%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 19 hours ago
60 Minute Opening Range Breakdown about 21 hours ago
60 Minute Opening Range Breakout about 21 hours ago
Up 5% about 21 hours ago
Gapped Up (Full) about 22 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aytu BioScience, Inc. Description

Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company's pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company, through its wholly-owned subsidiary Nuelle, Inc., is focused on women’s sexual wellbeing and intimacy.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Alcohol Prostate Cancer Urology In Vitro Hormones Fertility Ketones Estrogen Imaging Agent Infertility Testosterone Urinary Tract Infection In Vitro Diagnostic Device Androstanes Company's Pipeline Male Infertility Urinary Tract Infections

Is AYTU a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.45
52 Week Low 1.9046
Average Volume 21,092
200-Day Moving Average 2.76
50-Day Moving Average 2.34
20-Day Moving Average 2.18
10-Day Moving Average 2.08
Average True Range 0.12
RSI (14) 28.06
ADX 23.93
+DI 13.43
-DI 27.41
Chandelier Exit (Long, 3 ATRs) 2.08
Chandelier Exit (Short, 3 ATRs) 2.27
Upper Bollinger Bands 2.44
Lower Bollinger Band 1.92
Percent B (%b) 0.03
BandWidth 23.55
MACD Line -0.11
MACD Signal Line -0.09
MACD Histogram -0.0253
Fundamentals Value
Market Cap 10.79 Million
Num Shares 5.57 Million
EPS -6.31
Price-to-Earnings (P/E) Ratio -0.31
Price-to-Sales 0.16
Price-to-Book 0.50
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.12
Resistance 3 (R3) 2.13 2.08 2.09
Resistance 2 (R2) 2.08 2.03 2.07 2.08
Resistance 1 (R1) 2.01 2.01 1.98 2.00 2.07
Pivot Point 1.96 1.96 1.95 1.95 1.96
Support 1 (S1) 1.89 1.91 1.86 1.88 1.81
Support 2 (S2) 1.84 1.89 1.83 1.80
Support 3 (S3) 1.77 1.84 1.79
Support 4 (S4) 1.76